Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas. 2020

Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
Department of Neurosurgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

OBJECTIVE The aim of this study is to evaluate the survival rate and prognostic factors of anaplastic gliomas according to the 2016 World Health Organization classification, including extent of resection (EOR) as measured by contrast-enhanced T1-weighted magnetic resonance imaging (MRI) and the T2-weighted MRI. METHODS The records of 113 patients with anaplastic glioma who were newly diagnosed at our institute between 2000 and 2013 were retrospectively reviewed. There were 62 cases (54.9%) of anaplastic astrocytoma, isocitrate dehydrogenase (IDH) wild-type (AAw), 18 cases (16.0%) of anaplastic astrocytoma, IDH-mutant, and 33 cases (29.2%) of anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted. RESULTS The median overall survival (OS) was 48.4 months in the whole anaplastic glioma group and 21.5 months in AAw group. In multivariate analysis, age, preoperative Karnofsky Performance Scale score, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, postoperative tumor volume, and EOR measured from the T2 MRI sequence were significant prognostic factors. The EOR cut-off point for OS measured in contrast-enhanced T1-weighted MRI and T2-weighted MRI were 99.96% and 85.64%, respectively. CONCLUSIONS We found that complete resection of the contrast-enhanced portion (99.96%) and more than 85.64% resection of the non-enhanced portion of the tumor have prognostic impacts on patient survival from anaplastic glioma.

UI MeSH Term Description Entries
D007521 Isocitrate Dehydrogenase An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41. NAD Isocitrate Dehydrogenase,Isocitrate Dehydrogenase (NAD+),Isocitrate Dehydrogenase-I,Dehydrogenase, Isocitrate,Dehydrogenase, NAD Isocitrate,Isocitrate Dehydrogenase I,Isocitrate Dehydrogenase, NAD
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009837 Oligodendroglioma A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655) Oligodendroblastoma,Anaplastic Oligodendroglioma,Mixed Oligodendroglioma-Astrocytoma,Mixed Oligodendroglioma-Ependymoma,Oligodendroglioma, Adult,Oligodendroglioma, Childhood,Oligodendroglioma, Well-Differentiated,Well-Differentiated Oligodendroglioma,Adult Oligodendroglioma,Adult Oligodendrogliomas,Anaplastic Oligodendrogliomas,Childhood Oligodendroglioma,Childhood Oligodendrogliomas,Mixed Oligodendroglioma Astrocytoma,Mixed Oligodendroglioma Ependymoma,Mixed Oligodendroglioma-Astrocytomas,Mixed Oligodendroglioma-Ependymomas,Oligodendroblastomas,Oligodendroglioma, Anaplastic,Oligodendroglioma, Well Differentiated,Oligodendroglioma-Astrocytoma, Mixed,Oligodendroglioma-Astrocytomas, Mixed,Oligodendroglioma-Ependymoma, Mixed,Oligodendroglioma-Ependymomas, Mixed,Oligodendrogliomas,Oligodendrogliomas, Adult,Oligodendrogliomas, Anaplastic,Oligodendrogliomas, Childhood,Oligodendrogliomas, Well-Differentiated,Well Differentiated Oligodendroglioma,Well-Differentiated Oligodendrogliomas
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005260 Female Females

Related Publications

Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
July 2017, World neurosurgery,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
September 2013, Neurosurgery,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
September 2023, Journal of neurosurgery,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
October 1989, Journal of neurosurgery,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
January 2024, Clinical neurology and neurosurgery,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
August 2017, Journal of neuro-oncology,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
May 2020, Journal of neurosurgery,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
January 2003, Oncology,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
August 2017, World neurosurgery,
Je Beom Hong, and Tae Hoon Roh, and Seok-Gu Kang, and Se Hoon Kim, and Ju Hyung Moon, and Eui Hyun Kim, and Sung Soo Ahn, and Hye Jin Choi, and Jaeho Cho, and Chang-Ok Suh, and Jong Hee Chang
January 2003, Acta neurochirurgica. Supplement,
Copied contents to your clipboard!